- Home
- RBNE vs INDP Comparison
RBNE vs INDP Comparison
Compare RBNE & INDP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RBNE
- INDP
- Stock Information
- Founded
- RBNE 2024
- INDP 2000
- Country
- RBNE Cyprus
- INDP United States
- Employees
- RBNE N/A
- INDP N/A
- Industry
- RBNE Marine Transportation
- INDP Biotechnology: Pharmaceutical Preparations
- Sector
- RBNE Consumer Discretionary
- INDP Health Care
- Exchange
- RBNE Nasdaq
- INDP Nasdaq
- Market Cap
- RBNE 7.3M
- INDP 6.0M
- IPO Year
- RBNE N/A
- INDP N/A
- Fundamental
- Price
- RBNE $2.50
- INDP $7.30
- Analyst Decision
- RBNE
- INDP Strong Buy
- Analyst Count
- RBNE 0
- INDP 2
- Target Price
- RBNE N/A
- INDP $238.00
- AVG Volume (30 Days)
- RBNE 755.9K
- INDP 24.5K
- Earning Date
- RBNE 08-21-2025
- INDP 08-11-2025
- Dividend Yield
- RBNE N/A
- INDP N/A
- EPS Growth
- RBNE N/A
- INDP N/A
- EPS
- RBNE N/A
- INDP N/A
- Revenue
- RBNE N/A
- INDP N/A
- Revenue This Year
- RBNE N/A
- INDP N/A
- Revenue Next Year
- RBNE N/A
- INDP N/A
- P/E Ratio
- RBNE N/A
- INDP N/A
- Revenue Growth
- RBNE N/A
- INDP N/A
- 52 Week Low
- RBNE $2.38
- INDP $7.30
- 52 Week High
- RBNE $20.57
- INDP $59.36
- Technical
- Relative Strength Index (RSI)
- RBNE N/A
- INDP 31.62
- Support Level
- RBNE N/A
- INDP $8.00
- Resistance Level
- RBNE N/A
- INDP $10.57
- Average True Range (ATR)
- RBNE 0.00
- INDP 0.79
- MACD
- RBNE 0.00
- INDP -0.43
- Stochastic Oscillator
- RBNE 0.00
- INDP 0.00
About RBNE Robin Energy Ltd. Common Stock
Robin Energy Ltd operates a tanker vessel that engages in the transportation of refined petroleum products using its Handysize product tanker.
About INDP Indaptus Therapeutics Inc.
Indaptus Therapeutics Inc is a pre-clinical biotechnology company engaged in developing a novel and patented systemically-administered anti-cancer and anti-viral immunotherapy. It has developed a proprietary platform that exploits bacteria's natural ability to activate both innate and adaptive cellular immune pathways. The company's clinical candidate Decoy20, has the ability to elicit single-agent activity and durable anti-tumor responses in the combination setting against colorectal, hepatocellular, pancreatic carcinoma, and non-Hodgkin's lymphoma models.